A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer

NCT00405405 Phase 1 COMPLETED

To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer

Details

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase	Phase 1
Status	COMPLETED
Enrolment	13
Start date	2006-12
Completion	2010-06

Conditions

• Head and Neck Cancer
• Parotid Gland Cancer
• Thyroid Gland Cancer
• Melanoma
• Stage IV Head and Neck Cancer

Interventions

• Cisplatin
• Docetaxel
• Bevacizumab
• Erlotinib
• Radiotherapy

Primary outcomes

• Bevacizumab and Erlotinib Combined with Chemoradiotherapy for the Treatment of Advanced Head and Neck Cancer — Day 36
  To determine if bevacizumab and erlotinib can be safely combined with chemoradiotherapy for advanced head and neck cancer.

Countries

United States